A
AgentAngeloAURA
Michael
Back to book
UHNWI · Balanced, Global Discretionary·High priorityReputational

Hubertus & Carmen Schneider

Your reason trains the agent. No silent rejections.
Your insight tiles

Swap the full 5.8% Novartis position into Roche (same sector, active neurodegenerative pipeline).

Portfolio fit
88/100
Risk Δ
−0.1% portfolio vol
Expected return
+0.3% 12m est.
Sector shift
Health Care weight unchanged
Why now?
Novartis announced restructuring of its chronic-disease division, including a wind-down of two neurodegenerative programmes.
Why this client?
Hubertus explicitly asked us in March to audit our pharma names for neurology commitment. The family's foundation funds research in exactly this field.
Why this action?
Roche keeps the Health Care weight intact, the CIO list rates it Buy, and its neurology + diagnostics flywheel is materially exposed to the disease area the family cares about.

Novartis just shelved two neurodegenerative programmes [1], precisely the move Hubertus warned us about [3]. Roche is on the CIO Buy list [2] and remains one of the most active neurology platforms in Europe, a same-sector substitute that quietly honours the family's purpose.

[1]
Novartis restructures chronic-disease R&D
Reuters Health
"Two neurology programmes discontinued; capital redirected to oncology."
Jun 18, 2026
[2]
CIO Recommendation List, Roche Buy
CIO Office
"Diagnostics-pharma flywheel, durable franchises."
Jan 15, 2026
[3]
RM note, Hubertus pharma-pipeline audit
Salesforce CRM
"Hubertus replied with intense purpose, asking for full pipeline audit."
Mar 05, 2026
88
confidence
Reuters story 2d old, CIO note 5m old, RM note 107d old
What the model actually did

Matched the Novartis announcement against the CRM audit request, then ranked all CIO Buy-rated European pharma names by neurology R&D spend share. Roche led on both criteria.

Assumptions baked in
  • ·Hubertus's mandate intent from January (capital must act with purpose) still binds.
  • ·Roche keeps its current neurology pipeline scope through 2027.
What the AI does not know
  • ?Whether Hubertus has spoken to Dr. Frei this week about the Novartis cut.
  • ?How fast the foundation will need its next capital tranche, may favour delaying execution by a day.
  • 01Novartis often reverses programme cuts within 12 months, the rotation could lock in a sentiment-driven loss.
  • 02Roche's diagnostics business carries its own pricing-pressure risk, swapping one regulatory headline for another.
  • 03Hubertus is overseas this week, sending without a voice conversation first may feel impersonal.
  • Hold Novartis, write Hubertus a context note
    He has told us, in writing, he will not stay invested in names that cut neurology research.
  • Rotate into Lonza
    Wrong end of the pharma value chain, no direct neurology angle.
Track record: 3 similar cases · 3 of 3 approved within 48h. Last: Roche overweight in Q4 2025, approved same day.

Hubertus and Carmen rebuilt this mandate around Chloe. A quiet, principled rotation, no headline, no fanfare, says we understood without being told twice.

Use sparingly. Only when it is honestly true for this client, never as a sales overlay.
Incremental fees
+ CHF 7.4k / yr execution + discretionary uplift
Adjacent opportunity
Natural lead-in to a values-aligned thematic neurology basket, est. CHF 22k / yr advisory.
Retention argument
Acting on Chloe's cause without naming her is the single highest-trust signal we can send this year.
Mandate fit
Suitability
CIO universe
No regulatory flags. FINMA suitability constraints respected.